Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 43% Improvement Relative Risk Fluvoxamine for COVID-19  Marcec et al.  META ANALYSIS c19early.org Favors fluvoxamine Favors control

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference

Marcec et al., Journal of Infection, doi:10.1016/j.jinf.2022.11.011
Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
26th treatment shown to reduce risk in November 2021
 
*, now known with p = 0.00014 from 21 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Meta analysis of 7 fluvoxamine outpatient studies showing significantly lower hospitalization with treatment.
7 meta analyses show significant improvements with fluvoxamine for mortality Deng, hospitalization Deng, Deng (B), Lee, Lu, Marcec, Zhou, progression Zhou, and severity Nakhaee.
Currently there are 21 fluvoxamine for COVID-19 studies, showing 43% lower mortality [12‑62%], 42% lower ventilation [-151‑86%], 10% higher ICU admission [-72‑326%], 51% lower hospitalization [8‑73%], and 27% fewer cases [18‑35%].
risk of hospitalization, 43.0% lower, RR 0.57, p = 0.03.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Marcec et al., 17 Nov 2022, peer-reviewed, 3 authors. Contact: robert.likic@mef.hr, rlikic@kbc-zagreb.hr.
This PaperFluvoxamineAll
A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference
Robert Marcec, Vinko Michael Dodig, MD Robert Likic
Journal of Infection, doi:10.1016/j.jinf.2022.11.011
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Cheema, Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis, J. Infect
Lee, Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis, JAMA Netw. Open
Mccarthy, Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial, doi:10.1101/2022.10.17.22281178
Reis, Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob. Heal
{ 'DOI': '10.1016/j.jinf.2022.11.011', 'ISSN': ['0163-4453'], 'URL': 'http://dx.doi.org/10.1016/j.jinf.2022.11.011', 'alternative-id': ['S0163445322006727'], 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 ' 'patients: TOGETHER making a difference'}, {'label': 'Journal Title', 'name': 'journaltitle', 'value': 'Journal of Infection'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': 'https://doi.org/10.1016/j.jinf.2022.11.011'}, {'label': 'Content Type', 'name': 'content_type', 'value': 'simple-article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2022 The British Infection Association. Published by Elsevier Ltd. All rights ' 'reserved.'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-8750-2083', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Marcec', 'given': 'Robert', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0003-3562-3841', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Dodig', 'given': 'Vinko Michael', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-1413-4862', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Likic', 'given': 'Robert', 'sequence': 'additional'}], 'container-title': 'Journal of Infection', 'container-title-short': 'Journal of Infection', 'content-domain': { 'crossmark-restriction': True, 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'journalofinfection.com', 'elsevier.com', 'sciencedirect.com']}, 'created': { 'date-parts': [[2022, 11, 18]], 'date-time': '2022-11-18T14:20:18Z', 'timestamp': 1668781218000}, 'deposited': { 'date-parts': [[2022, 11, 18]], 'date-time': '2022-11-18T14:20:24Z', 'timestamp': 1668781224000}, 'indexed': { 'date-parts': [[2022, 11, 19]], 'date-time': '2022-11-19T05:52:21Z', 'timestamp': 1668837141993}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2022, 11]]}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 11, 1]], 'date-time': '2022-11-01T00:00:00Z', 'timestamp': 1667260800000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0163445322006727?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0163445322006727?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'prefix': '10.1016', 'published': {'date-parts': [[2022, 11]]}, 'published-print': {'date-parts': [[2022, 11]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'article-title': 'Efficacy and safety of fluvoxamine for the treatment of COVID-19 ' 'patients: A systematic review and meta-analysis', 'author': 'Cheema', 'first-page': '1', 'journal-title': 'J. Infect.', 'key': '10.1016/j.jinf.2022.11.011_bib0001', 'volume': '1', 'year': '2022'}, { 'DOI': '10.1001/jamanetworkopen.2022.6269', 'article-title': 'Fluvoxamine for Outpatient Management of COVID-19 to Prevent ' 'Hospitalization: A Systematic Review and Meta-analysis', 'author': 'Lee', 'doi-asserted-by': 'crossref', 'journal-title': 'JAMA Netw. Open', 'key': '10.1016/j.jinf.2022.11.011_bib0002', 'volume': '5', 'year': '2022'}, { 'DOI': '10.1016/S2214-109X(21)00448-4', 'article-title': 'Effect of early treatment with fluvoxamine on risk of emergency care ' 'and hospitalisation among patients with COVID-19: the TOGETHER ' 'randomised, platform clinical trial', 'author': 'Reis', 'doi-asserted-by': 'crossref', 'first-page': 'e42', 'journal-title': 'Lancet Glob. Heal.', 'key': '10.1016/j.jinf.2022.11.011_bib0003', 'volume': '10', 'year': '2022'}, { 'author': 'McCarthy', 'key': '10.1016/j.jinf.2022.11.011_bib0004', 'series-title': 'Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, ' 'Placebo-controlled, Randomized, Platform Clinical Trial', 'year': '2022'}], 'reference-count': 4, 'references-count': 4, 'relation': {}, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0163445322006727'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'subtitle': [], 'title': 'A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER ' 'making a difference', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit